164 related articles for article (PubMed ID: 37779518)
1. Dupilumab for cancer-associated refractory pruritus.
Talmon A; Elias S; Rubin L; Ribak Y; Ben Dori E; Shamriz O; Lotem M; Adini I; Tal Y
J Allergy Clin Immunol Glob; 2023 Aug; 2(3):100128. PubMed ID: 37779518
[TBL] [Abstract][Full Text] [Related]
2. Regression of metastatic malignant melanoma with dupilumab: A case report.
Marr JH; Al-Shammari A
Skin Health Dis; 2024 Jun; 4(3):e362. PubMed ID: 38846700
[TBL] [Abstract][Full Text] [Related]
3. Weight gain in patients with severe atopic dermatitis treated with dupilumab: a cohort study.
Johansson EK; Ivert LU; Bradley B; Lundqvist M; Bradley M
BMC Dermatol; 2020 Sep; 20(1):8. PubMed ID: 32962676
[TBL] [Abstract][Full Text] [Related]
4. Effects of Dupilumab on Itch-Related Events in Atopic Dermatitis: Implications for Assessing Treatment Efficacy in Clinical Practice.
Kishi R; Toyama S; Tominaga M; Kamata Y; Komiya E; Kaneko T; Suga Y; Takamori K
Cells; 2023 Jan; 12(2):. PubMed ID: 36672173
[TBL] [Abstract][Full Text] [Related]
5. Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
Beck LA; Deleuran M; Bissonnette R; de Bruin-Weller M; Galus R; Nakahara T; Seo SJ; Khokhar FA; Vakil J; Xiao J; Marco AR; Levit NA; O'Malley JT; Shabbir A
Am J Clin Dermatol; 2022 May; 23(3):393-408. PubMed ID: 35503163
[TBL] [Abstract][Full Text] [Related]
6. Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial.
Ständer S; Kwatra SG; Silverberg JI; Simpson EL; Thyssen JP; Yosipovitch G; Zhang F; Cameron MC; Cella RR; Valdez H; DiBonaventura M; Feeney C
Am J Clin Dermatol; 2023 Jan; 24(1):97-107. PubMed ID: 36512175
[TBL] [Abstract][Full Text] [Related]
7. Chronic Pruritus in Atopic Patients Treated with Dupilumab: Real Life Response and Related Parameters in 354 Patients.
Mastorino L; Rosset F; Gelato F; Ortoncelli M; Cavaliere G; Quaglino P; Ribero S
Pharmaceuticals (Basel); 2022 Jul; 15(7):. PubMed ID: 35890180
[TBL] [Abstract][Full Text] [Related]
8. Chronic Pruritus Responding to Dupilumab-A Case Series.
Zhai LL; Savage KT; Qiu CC; Jin A; Valdes-Rodriguez R; Mollanazar NK
Medicines (Basel); 2019 Jun; 6(3):. PubMed ID: 31261951
[TBL] [Abstract][Full Text] [Related]
9. Dupilumab: A review of its use in the treatment of atopic dermatitis.
Gooderham MJ; Hong HC; Eshtiaghi P; Papp KA
J Am Acad Dermatol; 2018 Mar; 78(3 Suppl 1):S28-S36. PubMed ID: 29471919
[TBL] [Abstract][Full Text] [Related]
10. Drug evaluation review: dupilumab in atopic dermatitis.
Hamilton JD; Ungar B; Guttman-Yassky E
Immunotherapy; 2015; 7(10):1043-58. PubMed ID: 26598956
[TBL] [Abstract][Full Text] [Related]
11. Dupilumab side effect in a patient with atopic dermatitis: a case report study.
Albader SS; Alharbi AA; Alenezi RF; Alsaif FM
Biologics; 2019; 13():79-82. PubMed ID: 31190731
[TBL] [Abstract][Full Text] [Related]
12. Exploration of biomarkers to predict clinical improvement of atopic dermatitis in patients treated with dupilumab: A study protocol.
Nakahara T; Izuhara K; Onozuka D; Nunomura S; Tamagawa-Mineoka R; Masuda K; Ichiyama S; Saeki H; Kabata Y; Abe R; Ohtsuki M; Kamiya K; Okano T; Miyagaki T; Ishiuji Y; Asahina A; Kawasaki H; Tanese K; Mitsui H; Kawamura T; Takeichi T; Akiyama M; Nishida E; Morita A; Tonomura K; Nakagawa Y; Sugawara K; Tateishi C; Kataoka Y; Fujimoto R; Kaneko S; Morita E; Tanaka A; Hide M; Aoki N; Sano S; Matsuda-Hirose H; Hatano Y; Takenaka M; Murota H; Katoh N; Furue M
Medicine (Baltimore); 2020 Sep; 99(38):e22043. PubMed ID: 32957324
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE Trial.
Simpson EL; Silverberg JI; Thyssen JP; Viguier M; Thaçi D; de Bruin-Weller M; Weidinger S; Chan G; DiBonaventura M; Biswas P; Feeney C; Koulias C; Cork MJ
Am J Clin Dermatol; 2023 Jul; 24(4):609-621. PubMed ID: 37213005
[TBL] [Abstract][Full Text] [Related]
14. The effectiveness and safety of dupilumab in the management of refractory prurigo nodularis in 45 Chinese patients: A real-life observational study.
Fang HY; Lian CH
J Dermatol; 2023 Aug; 50(8):1084-1087. PubMed ID: 37088954
[TBL] [Abstract][Full Text] [Related]
15. Dupilumab: human monoclonal antibody against IL-4Rα for moderate to severe atopic dermatitis.
Paton DM
Drugs Today (Barc); 2017 Sep; 53(9):477-487. PubMed ID: 29238761
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE).
Blauvelt A; Guttman-Yassky E; Paller AS; Simpson EL; Cork MJ; Weisman J; Browning J; Soong W; Sun X; Chen Z; Kosloski MP; Kamal MA; Delevry D; Chuang CC; O'Malley JT; Bansal A
Am J Clin Dermatol; 2022 May; 23(3):365-383. PubMed ID: 35567671
[TBL] [Abstract][Full Text] [Related]
17. IL-4 and IL-13 are not involved in IL-31-induced itch-associated scratching behaviour in mice.
Kawai R; Ichimasu N; Katagiri K
Exp Dermatol; 2024 Jun; 33(6):e15115. PubMed ID: 38855893
[TBL] [Abstract][Full Text] [Related]
18. Successful Use of Dupilumab in the Treatment of Acquired Perforating Dermatosis Associated with Atopic Dermatitis.
Gori N; De Luca E; Chiricozzi A; Sfregola S; Di Stefani A; Peris K
Case Rep Dermatol Med; 2024; 2024():6265608. PubMed ID: 38939121
[TBL] [Abstract][Full Text] [Related]
19. Dupilumab shows slow, steady effectiveness for intractable prurigo in patients with atopic dermatitis.
Takeuchi S; Inoue K; Kuretake K; Kiyomatsu-Oda M; Furue M
J Dermatol; 2021 May; 48(5):638-644. PubMed ID: 33742710
[TBL] [Abstract][Full Text] [Related]
20. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ).
de Bruin-Weller M; Thaçi D; Smith CH; Reich K; Cork MJ; Radin A; Zhang Q; Akinlade B; Gadkari A; Eckert L; Hultsch T; Chen Z; Pirozzi G; Graham NMH; Shumel B
Br J Dermatol; 2018 May; 178(5):1083-1101. PubMed ID: 29193016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
